Company / Operating Income
IOVANCE BIOTHERAPEUTICS, INC. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$403.4M
FY2025
5-year range
-$460.6M / -$342.7M
FY2021-FY2025
Trend
-2.0%
vs FY2024
Sector context
#181 of 204
Health Care
What the data says
IOVANCE BIOTHERAPEUTICS, INC.'s operating income of -$403M is lower than 89% of companies in the Health Care sector (FY2025). Improved from -$461M to -$403M over the past 2 years.
Based on SEC 10-K filings.
-$403M in FY2025.
Improved from -$461M to -$403M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 204This company -$403.4M Sector average $107.8M
▼
-474.3% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 2.0% year-over-year.
- Ranks #181 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$403.4M | -2.0% |
| FY2024 | -$395.3M | +14.2% |
| FY2023 | -$460.6M | -15.5% |
| FY2022 | -$398.9M | -16.4% |
| FY2021 | -$342.7M | -30.8% |
| FY2020 | -$261.9M | -26.6% |
| FY2019 | -$206.9M | -61.3% |
| FY2018 | -$128.3M | -38.1% |
| FY2017 | -$92.9M | -671.3% |
| FY2016 | -$12.0M | +46.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026